Advertisement

Surgical Endoscopy

, Volume 30, Issue 9, pp 3730–3740 | Cite as

Endoscopic versus percutaneous drainage of symptomatic pancreatic fluid collections: a 14-year experience from a tertiary hepatobiliary centre

  • Margaret G. KeaneEmail author
  • Shun Fung Sze
  • Natascha Cieplik
  • Sam Murray
  • Gavin J. Johnson
  • George J. Webster
  • Douglas Thorburn
  • Stephen P. PereiraEmail author
Open Access
Article

Abstract

Introduction

Endoscopic transmural drainage (ED) or percutaneous drainage (PD) has mostly replaced surgery for the initial management of patients with symptomatic pancreatic fluid collections (PFCs). This study aimed to compare outcomes for patients undergoing ED or PD of symptomatic PFCs.

Methods

Between January 2000 and December 2013, all patients who required PD or ED of a PFC were included. Rates of treatment success, length of hospital stay, adverse events, re-interventions and length of follow-up were recorded retrospectively in all cases.

Results

In total, 164 patients were included in the study; 109 patients underwent ED; and 55 had PD alone. During the 14-year study period, the incidence of ED increased and PD fell. In the 109 patients who were managed by ED, treatment success was considerably higher than in those managed by PD (70 vs. 31 %). Rates of procedural adverse events were higher in the ED cohort compared to the PD group (10 vs. 1 %), but patients managed by ED required fewer interventions (median of 1.8 vs. 3.3) had lower rates of residual collections (21 vs. 67 %) and need for surgical intervention (4 vs. 11 %). In the ED group, treatment success was similar for walled-off pancreatic necrosis (WOPN) and pseudocysts (67 vs. 72 %, P = 0.77). There were no procedure-related deaths.

Conclusion

Compared with PD, ED of symptomatic PFCs was associated with higher rates of treatment success, lower rates of re-intervention, including surgery and shorter lengths of hospital stay. Outcomes in WOPN were comparable to those in patients with pseudocysts.

Keywords

Acute pancreatitis Chronic pancreatitis Pseudocyst Walled-off pancreatic necrosis Endoscopic ultrasound Endoscopic drainage 

Pancreatic fluid collections (PFCs) are collections of pancreatic fluid or debris that are encased in a wall of granulation tissue. They occur following acute pancreatitis, pancreatic surgery, abdominal trauma or chronic obstruction of the pancreatic duct, e.g. in chronic pancreatitis or pancreatic malignancy [1, 2, 3]. PFCs are estimated to occur in 5–16 % [4] of patients with acute pancreatitis and up to 40 % of patients with chronic pancreatitis [5].

While most asymptomatic inflammatory pancreatic collections, especially if small (e.g. <4 cm), will resolve spontaneously and can be managed conservatively [6], once a PFC increases to 6 cm or becomes symptomatic (e.g. infection, abdominal pain, biliary or gastric outlet obstruction), rates of spontaneous resolution are much lower and drainage is recommended [7, 8, 9, 10, 11]. The management of asymptomatic PFCs larger than 6 cm remains debated, but conservative management is often advocated given the potential for procedure-associated morbidity in an asymptomatic patient [10].

PFCs may be drained surgically, by radiologically guided percutaneous drainage (PD), or endoscopically, usually by endoscopic transmural drainage (ED). Historically, surgery was considered the standard initial management for PFCs, but given its invasive nature, morbidity, longer length of hospital stay and increased associated costs, there has been a growing interest in less invasive approaches for the management of PFCs, such as PD or ED [2, 3, 12, 13, 14, 15].

The first reports of the endoscopic creation of a fistulous tract between a PFC and the gastrointestinal tract were published in the 1980s [16, 17, 18]. Since these early descriptions, the technique has evolved and now routinely combines endoscopic ultrasound (EUS) enabling the drainage of non-bulging collections and reducing associated adverse events [2, 3, 19, 20, 21, 22, 23.]

Previous studies have compared surgical drainage with PD [14, 24, 25, 26, 27] and ED [13]. One group compared all three approaches, but in this study, only a few patients underwent PD, so the final analysis focused on outcomes for surgical and ED [28]. A subsequent study did compare outcomes for PD and ED, but focused on outcomes in pseudocysts [29]. Increasingly, necrotic PFC are being managed by minimally invasive approaches given the morbidity associated with open surgical interventions [2, 3, 30], but there remains a lack of information about the optimal minimally invasive drainage method in different PFCs.

Study aim

The aim of this study is to compare the outcomes of endoscopic or percutaneous drainage in patients with symptomatic PFC.

Methods

Setting

A large regional hepatopancreaticobiliary centre based across two tertiary care hospitals: University College London Hospital NHS Foundation Trust (UCLH) and the Royal Free Hospital NHS Foundation Trust (RFH).

Design

This is a retrospective cohort study.

Ethical approval

The study was registered as a clinical audit at University College London NHS Foundation Trust and the Royal Free Hospital NHS Foundations Trust and conducted in accordance with the Helsinki Declaration [31].

Definitions

Pancreatic fluid collection (PFC)

PFC in this study was defined as measuring >4 cm on CT/MRCP and located within or adjacent to the pancreas, in patients with a documented history of acute or chronic pancreatitis, pancreatic surgery or malignancy.

Types of PFCs

PFCs were defined in accordance with the revised Atlanta criteria: [1]
  • Pseudocyst collection of fluid encapsulated within a well-defined inflammatory wall containing no solid components or necrosis. Present for >4 weeks.

  • Walled-off pancreatic necrosis (WOPN) mature, encapsulated collection of pancreatic ± peripancreatic necrosis that has a well-defined inflammatory wall. Present for >4 weeks.

Treatment success

Treatment success was defined as the successful insertion of a stent or drain with complete resolution or a decrease in the size of the PFC to ≤2 cm on follow-up CT.

Residual PFC

A residual collection was defined as the presence of a PFC (>2 cm), which did not resolve on imaging following percutaneous or endoscopic drainage.

Recurrent PFC

Recurrence was defined as the presence of a PFC on imaging after resolution of the initial collection.

Re-intervention

Re-intervention was defined as the need for repeat drainage or surgery owing to persistent symptoms in association with a residual PFC on follow-up imaging.

Length of stay

Length of hospital stay was defined as the time to discharge from the day of the first percutaneous drainage (percutaneous management group) or first endoscopic transmural drainage (endoscopic management group).

Infected collection

An infected PFC was diagnosed based on fever, raised inflammatory markers, radiological findings (e.g. gas bubbles within the PFC) or positive culture from the PFC following aspiration.

Procedure: EUS-guided transmural drainage

Prior to EUS, cross-sectional imaging (computed tomography (CT) or magnetic resonance imaging (MRI)/magnetic resonance cholangiopancreatography (MRCP)) was performed within 4 weeks, to determine the size and location of the cyst, as well as to evaluate for interposed vascular structures or evidence of pancreatic duct disruption necessitating a pancreatic stent.

The procedures were performed under conscious sedation or general anaesthesia, a linear array echoendoscope (Pentax Medical, UK or Olympus, UK) was used to ensure the distance between the gastric and/or duodenal wall, the PFC was <1 cm, and there were no interposed blood vessels on Doppler.

In the majority of cases, the PFC was accessed from the stomach using a cystotome (Cook Medical, Limerick, Ireland). In other cases, access was obtained using a needle knife or 19-gauge fine needle aspiration needle (ECHO-19; Cook Medical or Expect; Boston Scientific, Hemel Hempstead, UK). Entry was confirmed by aspiration of cyst contents, after which two 0.035-inch guidewires were then advanced into the PFC and allowed to coil within the cyst under fluoroscopic guidance, which was used in all cases. The tract was then dilated with a controlled radial expansion (CRE) wire-guided balloon (Boston Scientific) or Soehendra biliary dilator. Usually, two double-pigtail stents (7F) of various lengths were then inserted into the fistulotomy using a Teflon pusher catheter (Cook Medical). Cyst fluid was obtained and sent for Gram stain, culture and fluid amylase levels as clinically indicated.

Patients were discharged when clinically stable (aim within 24 h) and prescribed a short course of oral antibiotics for up to 5 days. They were then followed up in clinic 3–6 monthly as necessary. Transmural stents were generally removed 9–12 months after insertion, as long as the PFC had resolved on cross-sectional imaging. If patients remained symptomatic, and the PFC persisted or recurred, additional drainage was performed following discussion at the hepatopancreaticobiliary (HPB) multidisciplinary meeting.

Procedure: percutaneous drainage

Percutaneous drainage was performed by a HPB radiologist under CT, ultrasound (US) and/or fluoroscopic guidance. The PFC was identified, and a suitable access route selected, which avoided the spleen, interposed bowel and blood vessels. The skin was marked and local anaesthesia administered (subcutaneous injection of 1 % lidocaine). The PFC was then punctured under imaging guidance with an 18-gauge single-wall needle (Cook Medical). A Seldinger technique was then used to sequentially dilate the tract over a 0.035-inch, non-hydrophilic guidewire (Cook Medical). A multiple-side holed 8F–12F (Flexima APDL; Boston Scientific) locking catheter was then placed and secured to the skin with 2-0 nylon suture. Drain output was monitored daily, and decisions about upsizing, replacing or removing the drain were made based on subsequent imaging and the clinical progress of the patient.

Inclusion criteria

Patients with a PFC requiring percutaneous or endoscopic transmural drainage between 1 January 2000 and 31 December 2013.

Exclusion criteria

  • Patients <18 years.

  • PFC <4 cm in size or managed conservatively.

  • Patients who were managed by surgery (n = 13), EUS-guided fine needle aspiration (EUS-FNA) (n = 7) or endoscopic retrograde cholangiopancreatography (ERCP) and transpapillary drainage (n = 2) alone.

Data recorded

Cases were identified primarily from records of the benign HPB multidisciplinary team meetings, which are held weekly. In addition, the Pathology (CoPath histology database, Sunquest, Tucson AZ, USA), Endoscopy (GI reporting tool, Unisoft medical systems, UK) and Imaging (PACS: picture archiving and communication system, GE Healthcare, USA) databases were searched using the following terms, pseudocyst, walled-off necrosis, pancreatic fluid collection.

The electronic medical records of the included patients were reviewed, and information was recorded in an electronic spreadsheet. Data collected included demographic information (age, sex, hospital number), initial symptoms, history of acute or chronic pancreatitis or malignancy, family history of pancreatic cancer or relevant clinical syndrome and serum amylase on admission, where available. Cross-sectional imaging (CT and/or MR/MRCP) features that were recorded included size (maximal dimension), location, number of cystic lesions, presence of a necrosis, features of acute or chronic pancreatitis, dilatation of the pancreatic duct or biliary tree, communication of the cystic lesion with the main pancreatic duct, ascites, pleural effusion or the presence of features of portal hypertension. For patients undergoing endoscopy (ERCP or EUS), imaging features were recorded in addition to details of the drainage technique and cytology, histology or culture results where available. For patients ultimately referred for surgery, date of the operation, type of resection and final histology were recorded. Length of follow-up was calculated from first procedure to last clinic appointment attended, or date of clinic discharge, or death.

Statistical analyses

Statistical Package for Social Sciences for Windows, version 18.0 (SPSS Inc., Chicago, IL, USA), was used to perform all statistical analyses. Associations between malignancy and various clinical and radiographic characteristics were evaluated using a two-sample t test for continuous variables and a Chi-squared test for categorical variables.

Results

Between January 2000 and December 2013, 270 patients with a PFC were evaluated at UCLH and the RFH. In total, 84 patients were managed conservatively and 13 by surgery alone and were excluded from the study (Fig. 1). Two patients had ERCP and transpapillary drainage and seven EUS-guided fine needle aspiration (EUS-FNA) to dryness alone; these cases were also excluded. The 7 patients having EUS-FNA alone were initially referred for consideration of ED, but at the time of the procedure, ED was not performed because of small cyst size (n = 2) or phlegmon containing largely solid material (n = 5).
Fig. 1

Flow chart demonstrating patient selection and proportion of patients with pseudocysts and WOPN in each cohort. WOPN walled-off pancreatic necrosis, ERCP + TPD endoscopic retrograde cholangiopancreatography + transpapillary drainage, EUS-FNA endoscopic ultrasound and fine needle aspiration

Of the 164 patients included in the study, 109 patients underwent ED and 55 patients had PD alone (Fig. 1). During the study period, the overall number of patients undergoing drainage of their PFC increased annually, and the number of patients managed by PD alone decreased in favour of ED for both first-line and definitive management of a PFC (Fig. 2).
Fig. 2

Number of patients undergoing drainage of a pancreatic fluid collection annually during the study period

Diagnostic investigations

Clinical features and laboratory tests

Patient demographics are outlined in Table 1. The median age of patients undergoing ED was 55 years (range 22–84 years) compared to 50 years (range 20–87 years) for those receiving PD alone. Both groups had more male than female patients; 55 % (60) in the ED group and 67 % [37] in the PD group. The most common aetiologies of pancreatitis in both groups were gallstones and alcohol. In the ED group, more patients had gallstone pancreatitis (45 vs. 26 %; P = 0.01), and in the PD group, slightly more patients had alcohol-related pancreatitis (24 vs. 19 %). The cause of pancreatitis remained indeterminate in 25 % of the ED group and 38 % of those who underwent PD alone.
Table 1

Characteristics of patients undergoing drainage of PFCs by management subtype

 

Endoscopic transmural drainage (n = 109)

Percutaneous drainage (n = 55)

Median age of patient, years (range)

55 (22–84)

50 (20–87)

Sex

 Male

55 % (60)

67 % (37)

 Female

45 % (49)

33 % (18)

Aetiology

 Gallstones

45 % (50)

26 % (14)

 Alcohol

19 % (21)

24 % (13)

 Post-ERCP or EUS

3 % (3)

6 % (3)

 Hypercalcaemia

1 % (1)

2 % (1)

 Alcohol + gallstones

2 % (2)

 Hyperlipidaemia

1 % (1)

 Pancreatic/ampullary tumour

1 % (1)

2 % (1)

 Post-pancreatic surgery

1 % (1)

2 % (1)

 Tuberculosis

2 % (1)

 Incidental finding

2 % (2)

 Indeterminate

25 % (27)

38 % (21)

Cross-sectional imaging

Abdominal CT was used to confirm the presence of a PFC in all patients. Both CT and MRCP/MRI were performed in 46 % (76/164) of patients. The median size of the PFC managed by ED or PD was similar; 103 versus 102 mm, respectively. In both groups, approximately two-thirds of the collections were located within or adjacent to the body or tail of the pancreas. In total, 32 % of those undergoing ED and 42 % of those receiving PD had evidence of chronic pancreatitis on cross-sectional imaging immediately prior to drainage. The ED group contained fewer patients with necrotising pancreatitis (35 vs. 55 %). Evidence of portal hypertension on imaging was common in both groups, 49 % in the ED group and 42 % in the PD group (Table 2).
Table 2

Comparison of cross-sectional imaging features by management subtype

 

Endoscopic transmural drainage (n = 109)

Percutaneous drainage (n = 55)

Median size of PFC + range (mm)

103 (40–250)

102 (40–222)

Site

Head/neck

37 % (41)

36 % (20)

Body/tail

63 % (68)

64 % (35)

Acute pancreatitis

73 % (80)

76 % (42)

Chronic pancreatitis

32 % (35)

42 % (23)

Pancreatic necrosis

35 % (38)

55 % (30)

Pancreatic duct dilatation

39 % (43)

40 % (22)

Extrahepatic biliary dilation

35 % (38)

38 % (21)

Pseudoaneurysm

6 % [6 (2 haemorrhages)]

11 % [6 (4 haemorrhages)]

Ascites

11 % (12)

31 % (17)

Pleural effusion

16 % (17)

40 % (22)

Portal hypertension

49 % (53)

42 % (23)

Multiple pancreatic cysts

23 % (25)

35 % (19)

Lymph node enlargement

19 % (21)

13 % (7)

Management and outcomes

Almost all drains were placed more than 4 weeks after the onset of pancreatitis, with the exception of a few patients with an infected PFC. In the PD group, the median time to first drainage was 28 days (range 1–1444 days) compared to 101 days (range 7–3183 days) in the ED group.

Of the ED procedures undertaken, 35 % were performed in patients with WOPN (Table 3). Patients with WOPN undergoing ED were older than the pseudocyst group (60 vs. 51 years), had larger collections (119 vs. 100 mm) and had higher rates of portal hypertension (58 vs. 44 %). All patients had symptoms attributable to their cyst, and the most common indication for drainage was pain. Clinical signs of infection were more frequent in the WOPN group (76 vs. 37 %). When fluid was aspirated from a PFC for culture, it was almost always positive (WOPN 96 vs. pseudocysts 100 %). Most fluid aspirates had mixed growth (WOPN 46 vs. pseudocysts 50 %), and patients with WOPN were co-infected with methicillin-resistant Staphylococcus aureus (MRSA) and candida in 17 and 25 % of cases, respectively, compared to 5 and 9 % in pseudocysts (Table 3).
Table 3

Comparison of clinical outcomes of endoscopic transmural drainage in walled-off pancreatic necrosis (WOPN) and pseudocysts

 

WOPN

Patients = 38

Procedures = 46

Pseudocyst

Patients = 71

Procedures = 81

Median age of patient, years (range)

60 (22–84)

51 (26–84)

Median maximal diameter—mm (range)

119 (67–200)

100 (40–250)

Portal hypertension % (n)

58 % (22)

44 % (31)

Reason for drainage % (n)

 Pain

24 % (11)

43 % (35)

 Increasing size + pain

35 % (16)

32 % (26)

 Infection

28 % (13)

11 % (9)

 Gastric outlet obstruction

7 % (3)

6 % (5)

 Unknown

7 % (3)

7 % (6)

Sedation % (n)

 Conscious sedation

97 % (37)

98 % (58)

 General anaesthesia

3 % (1)

2 % (1)

 Unknown

(8)

(23)

Approach % (n)

 Transgastric

98 % (42)

91 % (60)

 Transduodenal

2 % (1)

9 % (6)

 Unknown

(3)

(15)

Cystotome used 5 (n)

74 % (34)

67 % (54)

Number of stents inserted % (n)

 Plastic

  0 (Failed stent insertion/procedure abandoned)

2 % (1)

10 % (8)

  1

9 % (4)

10 % (8)

  2

70 % (32)

62 % (50)

  3

4 % (2)

6 % (5)

  4

2 % (1)

0 % (0)

  Unknown

7 % (3)

10 % (8)

 Fully covered self-expanding metal stents (FCSEMS)

7 % (3)

3 % (2)

Infection % (n)

 Clinical signs of infection

76 % (29/38)

37 % (26/71)

 Positive pancreatic fluid culture

96 % (23/24)

100 % (22/22)

 Mixed growth

46 % (11)

50 % (11)

 Streptococcus

0 % (0)

18 % (4)

 Staphylococcus

17 % (4)

14 % (3)

 E coli

13 % (3)

5 % (1)

 Enterococcus

8 % (2)

5 % (1)

Other

16 % (4)

10 % (2)

Pancreatic fluid—co-infection

 MRSA

17 % (4)

5 % (1)

 Candida

25 % (6)

9 % (2)

Treatment success % (n)

67 % (31/46)

72 % (58/81)

 Failed stent insertion/procedure abandoned

2 % (1/46)

10 % (8/81—2 cases required a further procedure)

 Further procedure required

37 % (14/38)

24 % (17/71)

Adverse events % (n)

7 % (3)

12 % (10)

 Stent migration

2 % (1)

4 % (3)

 Haemorrhage—transfusion required

0 % (0)

3 % (2:1—acute, 1—delayed)

 Pneumoperitoneum

2 % (1)

3 % (2)

 Oesophageal perforation

0 % (0)

3 % (2)

 Aspiration pneumonia

2 % (1)

0 % (0)

 Pneumothorax

0 % (0)

1 % (1)

Residual PFC % (n)

22 % (10/46)

20 % (16/81)

Recurrent PFC % (n)

9 % (4/46)

5 % (4/81)

Number of drainage interventions required

 Mean number of interventions (range)

2.3 (1–7)

1.5 (1–4)

 Mean pre-ED (range)

0.9 (0–6)

0.3 (0–3)

 Mean post-ED (range)

0.5 (0–3)

0.3 (0–3)

 Surgical intervention ultimately required—% (n)

5 % (2)

3 % (2)

Length of stay: median number of days in hospital post-ED (range)

4 (0–36)

4 (0–63)

Almost all (98 % (94/96)) ED were performed under conscious sedation. The puncture was attempted through the transgastric route in 98 % of the WOPN and 91 % of pseudocysts. A 10F cystotome (Cook Medical) was used in approximately two-thirds of cases. Stent insertion was successful in 98 % of WOPN and 90 % of pseudocysts. A median of two plastic double-pigtail stents (range 1–4) were inserted. A fully covered self-expanding metal stent (FCSEMS) (NAGI stent, Taewoong Medical, Gyeonggi-do, Korea) was inserted in 4.6 % (5/109) of cases. Treatment success was similar in both the WOPN and pseudocyst groups (67 % (31/46) vs. 72 % (58/81), P = 0.77). The median length of stay post-ED was 4 days and did not differ between patients with pseudocysts and WOPN collections, nor did the need for a further procedure (31 vs. 21 %, P = 0.11). Adverse events occurred in 10 % of cases and were similar in both the WOPN and pseudocyst groups. Adverse events included four episodes of stent migration, three cases of pneumoperitoneum (one managed conservatively with percutaneous drainage, while two underwent laparotomy), two oesophageal perforations which required laparotomy, two episodes of gastrointestinal bleeding requiring blood transfusion and endoscopic or radiological intervention, one pneumothorax which required drainage and one aspiration pneumonia. No patients died in the 30 days following the procedure.

In the 55 patients who were managed by PD, 18 % (10/55) of the patients had the drain placed transgastrically, of which 8 were internalised. Treatment success in the PD group was considerably lower than those managed by ED [31 % (30/97) vs. 70 % (89/127)]. During the median follow-up period of 11 (0–131) months in the ED group and 17 (1–150) months in the PD group, rates of failed drain insertion and adverse events were lower in the PD cohort compared to the ED group, 1 and 1 % versus 7 and 10 %, respectively. However, patients managed by PD alone required more interventions (median of 3.3 vs. 1.8), had higher rates of residual collections (67 vs. 21 %) and ultimately a higher proportion required surgical management (11 vs. 4 %) and had a longer hospital stay (median 42 vs. 4 days) (Table 4).
Table 4

Comparison of clinical outcomes following endoscopic transmural or percutaneous drainage

 

Endoscopic transmural drainage

Patients = 109

Procedures = 127

Percutaneous drainage

Patients = 55

Procedures = 97

Treatment success  % (n)

 Overall

70 % (89/127)

31 % (30/97)

 WOPN

67 % (31/46)

23 % (15/65)

 Pseudocyst

72 % (58/81)

47 % (15/32)

Failed drain/stent insertion  % (n):

 Overall

7 % (9)

1 % (1)

 WOPN

2 % (1)

2 % (1)

 Pseudocyst

10 % (8)

0 % (0)

Rate of adverse events  % (n)

10 % (13)

2 % (2)

Adverse events

Stent migration (4)

Pneumoperitoneum (3)—percutaneous drainage × 1 and a laparotomy x2

Oesophageal perforation (2)—both required laparotomy

Gastrointestinal bleeding (2)—both required transfusion and endoscopic or radiological intervention

Pneumothorax (1)—chest drain

Aspiration pneumonia (1)

Pancreatic fistula (2)—both managed conservatively

Median hospital stay post-procedure (range)

4 (0–63)

42 (2–199)

30-day mortality  % (n):

0 % (0)

7 % (4)—all due to the complications of severe acute pancreatitis

Residual PFC  % (n)

 Overall

21 % (26)

67 % (65)

 WOPN

22 % (10)

74 % (48)

 Pseudocyst

20 % (16)

53 % (17)

Recurrent PFC  % (n):

6 % (8)

2 % (2)

Number of drainage interventions required:

 Mean number of interventions (range)

1.8 (1–7)

3.3 (1–11)

 Mean pre-ED (range)

0.5 (0–6)

1.1 (0–10)

 Mean post-ED (range)

0.3 (0–3)

1.2 (0–10)

 Surgical intervention ultimately required

4 % (4)

11 % (6)

Patients managed by percutaneous drainage had an external drain in situ for a median of 56 days (range 3–651 days). Cystenterostomy stents were left in situ for a median of 277 days (range 20–1015 days) before removal.

Discussion

Historically, PFCs have been managed by surgical drainage. However, the associated morbidity and mortality of pancreatic surgery have resulted in a growing interest in alternative minimally invasive techniques. A recent randomised study of 40 patients compared ED and surgical drainage. ED was found to have comparable efficacy with similar rates of adverse events but with a shorter hospital stay [15]. In the present study, ED was associated with higher rates of treatment success (70 vs. 31 %), a shorter length of hospital stay and fewer subsequent interventions, when compared to PD.

When compared to other case series, the rate of initial technical success was similar, but overall treatment success in this study (70 %) was lower than previously reported [3, 30]. However, it was comparable to series from centres with a longer follow-up time allowing sufficient time to diagnose recurrent or residual collections [32] and those series which included a high proportion of complex cases (e.g. WOPN and portal hypertension) [2, 3]. Other groups have reported much lower rates of treatment success when managing necrotic collections (25 vs. 93 %) [2], but in this study, treatment success rates between WOPN and pseudocysts were comparable (67 vs 72 %). This may reflect differences in technique such as the insertion of more than two plastic stents or the use of FCSEMS in the management of these collections.

Adverse events occurred in 10 % (n = 13) of the ED cases, but all were successfully managed during the same hospitalisation. Rates were comparable to those reported in other ED studies and were similar or lower than those following surgical drainage of a PFC [2, 3, 15, 23, 33, 34]. Other authors have also reported higher adverse events when draining organised necrosis [2, 3]. This was not the case in our series, where in fact adverse events were slightly lower in the WOPN cohort compared to the pseudocyst group (7 vs 12 %). The 30-day mortality following ED in this cohort was zero, compared to 0–7 % in other series [2, 3, 15, 20, 23, 35, 36, 37, 38].

Bacterial or fungal colonisation and systemic infection are common sequelae of chronic PFC, particularly in the presence of necrosis. As in this series, typically a range of bacteria is isolated and fungal contamination is present in up to a quarter of cases with WOPN [39]. EUS-guided aspiration is therefore increasingly recommended to guide antibiotic management [40]. Although not performed routinely in most centres, it appears to be a useful strategy for guiding antibiotic and antifungal choice in the management of infected PFCs.

In patients in this series managed by PD alone, rates of treatment success were low and further procedures were commonly required, similar to outcomes reported in other PD series [14, 41, 42, 43, 44, 45]. PD also requires patients to have a long-term external drain (median time in situ of 56 days), which is commonly disliked by patients and has been associated with the development of chronic pancreatic cutaneous fistulas [14, 41, 42, 44]. In our series, although patients managed by PD had a longer length of stay in hospital, rates of pancreatic cutaneous fistulas were much lower (2 %) than previously reported, which may be because a proportion (18 %) of the percutaneous drains in our series were sited transgastrically, of which most (80 %) were ultimately converted to an endoscopic cystenterostomy.

One of the limitations of our study was that it was conducted retrospectively. Outcomes for the PD group may have been inferior due to the inclusion of patients with more severe disease as evidenced by higher rates of necrosis, ascites, pleural effusions, shorter time to first drainage (28 vs. 101 days), and that four patients died due to the complications of severe pancreatitis in this cohort.

Conclusions

ED is increasingly employed in the management of PFC. This large series demonstrated superior rates of treatment success, need for subsequent intervention and shorter length of stay in hospital compared to patients managed by PD alone. Outcomes and adverse events were similar for WOPN and pseudocysts, supporting the use of ED in the management of complex PFCs. Further high-quality studies are needed to fully define optimal pathways for the use of ED in the management of PFC.

Notes

Acknowledgments

Part of this work was undertaken at UCLH/UCL, which receives a proportion of funding from the Department of Health’s National Institute for Health Research (NIHR) Biomedical Research Centres funding scheme.

Compliance with ethical standards

Disclosures

Dr Keane, Dr Sze, Dr Cieplik, Dr Murray, Dr Johnson, Dr Webster, Dr Thorburn and Professor Pereira have no conflicts of interest or financial ties to disclose.

References

  1. 1.
    Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG et al (2013) Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus. Gut 62(1):102–111CrossRefPubMedGoogle Scholar
  2. 2.
    Hookey LC, Debroux S, Delhaye M, Arvanitakis M, Le Moine O, Deviere J (2006) Endoscopic drainage of pancreatic-fluid collections in 116 patients: a comparison of etiologies, drainage techniques, and outcomes. Gastrointest Endosc 63(4):635–643CrossRefPubMedGoogle Scholar
  3. 3.
    Varadarajulu S, Bang JY, Phadnis MA, Christein JD, Wilcox CM (2011) Endoscopic transmural drainage of peripancreatic fluid collections: outcomes and predictors of treatment success in 211 consecutive patients. J Gastrointest Surg 15(11):2080–2088CrossRefPubMedGoogle Scholar
  4. 4.
    Andersson B, Nilsson E, Willner J, Andersson R (2006) Treatment and outcome in pancreatic pseudocysts. Scand J Gastroenterol 41(6):751–756CrossRefPubMedGoogle Scholar
  5. 5.
    Aghdassi A, Mayerle J, Kraft M, Sielenkamper AW, Heidecke CD, Lerch MM (2008) Diagnosis and treatment of pancreatic pseudocysts in chronic pancreatitis. Pancreas 36(2):105–112CrossRefPubMedGoogle Scholar
  6. 6.
    Vitas GJ, Sarr MG (1992) Selected management of pancreatic pseudocysts: operative versus expectant management. Surgery 111(2):123–130PubMedGoogle Scholar
  7. 7.
    Smits ME, Rauws EA, Tytgat GN, Huibregtse K (1995) The efficacy of endoscopic treatment of pancreatic pseudocysts. Gastrointest Endosc 42(3):202–207CrossRefPubMedGoogle Scholar
  8. 8.
    Seewald S, Ang TL, Teng KC, Soehendra N (2009) EUS-guided drainage of pancreatic pseudocysts, abscesses and infected necrosis. Dig Endosc 21(Suppl 1):S61–S65CrossRefPubMedGoogle Scholar
  9. 9.
    Bergman S, Melvin WS (2007) Operative and nonoperative management of pancreatic pseudocysts. Surg Clin N Am 87(6):1447–1460CrossRefGoogle Scholar
  10. 10.
    Beebe DS, Bubrick MP, Onstad GR, Hitchcock CR (1984) Management of pancreatic pseudocysts. Surg Gynecol Obstet 159(6):562–564PubMedGoogle Scholar
  11. 11.
    Gouyon B, Levy P, Ruszniewski P, Zins M, Hammel P, Vilgrain V et al (1997) Predictive factors in the outcome of pseudocysts complicating alcoholic chronic pancreatitis. Gut 41(6):821–825CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Soliani P, Franzini C, Ziegler S, Del Rio P, Dell’Abate P, Piccolo D et al (2004) Pancreatic pseudocysts following acute pancreatitis: risk factors influencing therapeutic outcomes. JOP J Pancreas 5(5):338–347Google Scholar
  13. 13.
    Varadarajulu S, Lopes TL, Wilcox CM, Drelichman ER, Kilgore ML, Christein JD (2008) EUS versus surgical cyst-gastrostomy for management of pancreatic pseudocysts. Gastrointest Endosc 68(4):649–655CrossRefPubMedGoogle Scholar
  14. 14.
    Adams DB, Anderson MC (1992) Percutaneous catheter drainage compared with internal drainage in the management of pancreatic pseudocyst. Ann Surg 215(6):571–576 discussion 6-8 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Varadarajulu S, Bang JY, Sutton BS, Trevino JM, Christein JD, Wilcox CM (2013) Equal efficacy of endoscopic and surgical cystogastrostomy for pancreatic pseudocyst drainage in a randomized trial. Gastroenterology 145(3):583–590CrossRefPubMedGoogle Scholar
  16. 16.
    Cremer M, Deviere J, Engelholm L (1989) Endoscopic management of cysts and pseudocysts in chronic pancreatitis: long-term follow-up after 7 years of experience. Gastrointest Endosc 35(1):1–9CrossRefPubMedGoogle Scholar
  17. 17.
    Hershfield NB (1984) Drainage of a pancreatic pseudocyst at ERCP. Gastrointest Endosc 30(4):269–270CrossRefPubMedGoogle Scholar
  18. 18.
    Kozarek RA, Brayko CM, Harlan J, Sanowski RA, Cintora I, Kovac A (1985) Endoscopic drainage of pancreatic pseudocysts. Gastrointest Endosc 31(5):322–327CrossRefPubMedGoogle Scholar
  19. 19.
    Ahn JY, Seo DW, Eum J, Song TJ, Moon SH, Park DH et al (2010) Single-step EUS-guided transmural drainage of pancreatic pseudocysts: analysis of technical feasibility, efficacy, and safety. Gut Liver 4(4):524–529CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lopes CV, Pesenti C, Bories E, Caillol F, Giovannini M (2007) Endoscopic-ultrasound-guided endoscopic transmural drainage of pancreatic pseudocysts and abscesses. Scand J Gastroenterol 42(4):524–529CrossRefPubMedGoogle Scholar
  21. 21.
    Kruger M, Schneider AS, Manns MP, Meier PN (2006) Endoscopic management of pancreatic pseudocysts or abscesses after an EUS-guided 1-step procedure for initial access. Gastrointest Endosc 63(3):409–416CrossRefPubMedGoogle Scholar
  22. 22.
    Antillon MR, Shah RJ, Stiegmann G, Chen YK (2006) Single-step EUS-guided transmural drainage of simple and complicated pancreatic pseudocysts. Gastrointest Endosc 63(6):797–803CrossRefPubMedGoogle Scholar
  23. 23.
    Varadarajulu S, Tamhane A, Blakely J (2008) Graded dilation technique for EUS-guided drainage of peripancreatic fluid collections: an assessment of outcomes and complications and technical proficiency (with video). Gastrointest Endosc 68(4):656–666CrossRefPubMedGoogle Scholar
  24. 24.
    Lang EK, Paolini RM, Pottmeyer A (1991) The efficacy of palliative and definitive percutaneous versus surgical drainage of pancreatic abscesses and pseudocysts: a prospective study of 85 patients. South Med J 84(1):55–64CrossRefPubMedGoogle Scholar
  25. 25.
    Spivak H, Galloway JR, Amerson JR, Fink AS, Branum GD, Redvanly RD et al (1998) Management of pancreatic pseudocysts. J Am Coll Surg 186(5):507–511CrossRefPubMedGoogle Scholar
  26. 26.
    Sanfey H, Aguilar M, Jones RS (1994) Pseudocysts of the pancreas, a review of 97 cases. Am Surg 60(9):661–668PubMedGoogle Scholar
  27. 27.
    Heider R, Meyer AA, Galanko JA, Behrns KE (1999) Percutaneous drainage of pancreatic pseudocysts is associated with a higher failure rate than surgical treatment in unselected patients. Ann Surg 229(6):781–787 (discussion 7–9) CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Johnson MD, Walsh RM, Henderson JM, Brown N, Ponsky J, Dumot J et al (2009) Surgical versus nonsurgical management of pancreatic pseudocysts. J Clin Gastroenterol 43(6):586–590CrossRefPubMedGoogle Scholar
  29. 29.
    Akshintala VS, Saxena P, Zaheer A, Rana U, Hutfless SM, Lennon AM et al (2014) A comparative evaluation of outcomes of endoscopic versus percutaneous drainage for symptomatic pancreatic pseudocysts. Gastrointest Endosc 79(6):921–928 (quiz 83 e2, 83 e5) CrossRefPubMedGoogle Scholar
  30. 30.
    Mukai S, Itoi T, Sofuni A, Itokawa F, Kurihara T, Tsuchiya T et al (2015) Expanding endoscopic interventions for pancreatic pseudocyst and walled-off necrosis. J Gastroenterol 50(2):211–220CrossRefPubMedGoogle Scholar
  31. 31.
    World Medical Association Declaration of Helsinki (1997) Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc Res 35(1):2–3CrossRefGoogle Scholar
  32. 32.
    Ng PY, Rasmussen DN, Vilmann P, Hassan H, Gheorman V, Burtea D et al (2013) Endoscopic ultrasound-guided drainage of pancreatic pseudocysts: medium-term assessment of outcomes and complications. Endosc Ultrasound 2(4):199–203CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Ahlawat SK, Charabaty-Pishvaian A, Jackson PG, Haddad NG (2006) Single-step EUS-guided pancreatic pseudocyst drainage using a large channel linear array echoendoscope and cystotome: results in 11 patients. JOP J Pancreas 7(6):616–624Google Scholar
  34. 34.
    Yasuda I, Iwata K, Mukai T, Iwashita T, Moriwaki H (2009) EUS-guided pancreatic pseudocyst drainage. Dig Endosc 21(Suppl 1):S82–S86CrossRefPubMedGoogle Scholar
  35. 35.
    Vosoghi M, Sial S, Garrett B, Feng J, Lee T, Stabile BE et al (2002) EUS-guided pancreatic pseudocyst drainage: review and experience at Harbor-UCLA Medical Center. MedGenMed Med Gen Med 4(3):2Google Scholar
  36. 36.
    Azar RR, Oh YS, Janec EM, Early DS, Jonnalagadda SS, Edmundowicz SA (2006) Wire-guided pancreatic pseudocyst drainage by using a modified needle knife and therapeutic echoendoscope. Gastrointest Endosc 63(4):688–692CrossRefPubMedGoogle Scholar
  37. 37.
    Inui K, Yoshino J, Okushima K, Miyoshi H, Nakamura Y, Watanabe S et al (2001) EUS-guided one-step drainage of pancreatic pseudocysts: experience in 3 patients. Gastrointest Endosc 54(1):87–89CrossRefPubMedGoogle Scholar
  38. 38.
    Giovannini M, Bernardini D, Seitz JF (1998) Cystogastrotomy entirely performed under endosonography guidance for pancreatic pseudocyst: results in six patients. Gastrointest Endosc 48(2):200–203CrossRefPubMedGoogle Scholar
  39. 39.
    De Waele JJ, Rello J, Anzueto A, Moreno R, Lipman J, Sakr Y et al (2014) Infections and use of antibiotics in patients admitted for severe acute pancreatitis: data from the EPIC II study. Surg Infect 15(4):394–398CrossRefGoogle Scholar
  40. 40.
    Negm AA, Poos H, Kruck E, Vonberg RP, Domagk D, Madisch A et al (2013) Microbiologic analysis of peri-pancreatic fluid collected during EUS in patients with pancreatitis: impact on antibiotic therapy. Gastrointest Endosc 78(2):303–311CrossRefPubMedGoogle Scholar
  41. 41.
    Adams DB, Anderson MC (1992) Changing concepts in the surgical management of pancreatic pseudocysts. Am Surg 58(3):173–180PubMedGoogle Scholar
  42. 42.
    Freeny PC, Lewis GP, Traverso LW, Ryan JA (1988) Infected pancreatic fluid collections: percutaneous catheter drainage. Radiology 167(2):435–441CrossRefPubMedGoogle Scholar
  43. 43.
    vanSonnenberg E, Wittich GR, Casola G, Brannigan TC, Karnel F, Stabile BE et al (1989) Percutaneous drainage of infected and noninfected pancreatic pseudocysts: experience in 101 cases. Radiology 170(3 Pt 1):757–761CrossRefPubMedGoogle Scholar
  44. 44.
    D’Agostino HB, vanSonnenberg E, Sanchez RB, Goodacre BW, Villaveiran RG, Lyche K (1993) Treatment of pancreatic pseudocysts with percutaneous drainage and octreotide. Work in progress. Radiology 187(3):685–688CrossRefPubMedGoogle Scholar
  45. 45.
    Neff R (2001) Pancreatic pseudocysts and fluid collections: percutaneous approaches. Surg Clin N Am 81(2):399–403CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2015

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Margaret G. Keane
    • 1
    Email author
  • Shun Fung Sze
    • 1
  • Natascha Cieplik
    • 1
  • Sam Murray
    • 2
  • Gavin J. Johnson
    • 2
  • George J. Webster
    • 2
  • Douglas Thorburn
    • 1
  • Stephen P. Pereira
    • 1
    Email author
  1. 1.Institute for Liver and Digestive Health, Royal Free HospitalUniversity College LondonLondonUK
  2. 2.Department of GastroenterologyUniversity College London Hospitals NHS Foundation TrustLondonUK

Personalised recommendations